Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Decreased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 3.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,512 shares of the specialty pharmaceutical company’s stock after selling 1,383 shares during the period. Mutual of America Capital Management LLC owned 0.06% of Jazz Pharmaceuticals worth $4,517,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Rise Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 203 shares during the period. Cape Investment Advisory Inc. raised its stake in shares of Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 292 shares in the last quarter. Headinvest LLC acquired a new stake in Jazz Pharmaceuticals in the third quarter worth about $56,000. Assetmark Inc. grew its position in Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 119 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. increased its stake in Jazz Pharmaceuticals by 254.5% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 336 shares during the period. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Truist Financial reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. StockNews.com cut Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 5th. Barclays dropped their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Finally, UBS Group cut their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a report on Tuesday, July 2nd. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $188.62.

Check Out Our Latest Stock Analysis on JAZZ

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Trading Up 1.7 %

NASDAQ JAZZ opened at $102.23 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $6.45 billion, a PE ratio of 21.08, a price-to-earnings-growth ratio of 1.55 and a beta of 0.58. The firm’s fifty day simple moving average is $107.88 and its 200-day simple moving average is $115.67. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Further Reading

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.